Figure 3.
The figures present the adjusted mean values for each continuous outcome measure: a: annual prednisone course rate; b: annual urgent care rate; c: prebronchodilator FEV1 % predicted; d: prebronchodilator FEV1/FVC; e: bronchodilator reversibility, f: log methacholine FEV1 PC20; g: total eosinophil count; and h: serum IgE in the remitting (
), periodic (
), persistent (
) asthma groups during 9 years of follow-up after randomization in the CAMP trial.
